Cerebral Dopamine Neurotrophic Factor (CDNF) is a promising innovative drug candidate for the treatment of neurodegenerative diseases. This unique compound is a member of a novel family of unconventional neurotrophic factors which is structurally and mechanistically very distinct from all known neurotrophic factors. Specifically CDNF acts via a multimodal mechanism that involves modulation of endoplasmic reticulum (ER) stress, a-synuclein aggregation and toxicity, and reduced neuroinflammation. CDNF is patented internationally by Herantis.
In preclinical studies it has definitively been shown to be safe and effective. In particular it protects and regenerates dopamine-generating cells in the midbrain, suggesting potential for disease modification of Parkinsons Disease PD. It has shown efficacy in both motor and non-motor symptoms of PD in rodent and primate models of Parkinsons Disease.
CDNF has entered the clinic where its profile is further being evaluated for safety and efficacy. A Phase I-II study has been successfully completed which has established safety of the product, and preliminary indications of efficacy in patients.